卵巢类固醇对经前烦躁障碍女性的差异化效应:重复与扩展研究
该研究在扩大的样本中重复并扩展了先前发现:经前烦躁障碍(PMDD)患者在卵巢激素抑制期间症状缓解,在雌二醇或黄体酮添加后症状复现。
要点
- PMDD患者卵巢抑制后症状周期性消失,添加雌二醇或黄体酮后情感症状复现。
- PMDD患者中易怒和情绪波动与黄体酮关联比雌二醇更紧密。
- 腹胀和食物渴求在PMDD患者中严重度更高,不随激素条件变化。
核心结论
- PMDD患者卵巢抑制可消除症状周期性,添加卵巢类固醇后症状复现,健康对照无此表现。
- PMDD中易怒和情绪波动与黄体酮关联比雌二醇更紧密。
研究设计与样本
- 三种条件为:促性腺激素释放激素激动剂亮丙瑞林诱导的卵巢抑制、亮丙瑞林+雌二醇添加、亮丙瑞林+黄体酮添加。
主要发现
- 情感症状(焦虑、悲伤、易怒、情绪波动)存在显著诊断主效应和诊断×激素交互效应,PMDD患者在雌二醇和黄体酮添加期间症状严重度评分较单用亮丙瑞林显著升高。
- 与健康对照相比,PMDD患者在每次添加期间症状评分均显著更高。
- 腹胀和食物渴求在PMDD患者中严重度更高,与激素条件无关。
- 乳房疼痛在雌二醇添加期间较单用亮丙瑞林和黄体酮添加时严重度增加。
关键数值与推荐
- 比较单用亮丙瑞林最后8周(第12周中的后8周)与雌二醇添加前4周、黄体酮添加前4周的症状评分。
临床怎么用
- 卵巢激素抑制可消除PMDD症状周期性,添加雌二醇或黄体酮后症状复现,支持激素相关行为表型。
- PMDD中易怒和情绪波动与黄体酮关联更密切,提示黄体酮在症状发生中作用更突出。
局限性
- 类固醇信号传导改变的确切机制仍需进一步表征。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The authors previously demonstrated that symptoms of premenstrual dysphoric disorder (PMDD) remit during ovarian hormone suppression and recur after estradiol or progesterone is reintroduced (addback). In this study, using a substantially expanded sample, they aimed to 1) evaluate the specific contributions of estradiol and progesterone to symptom development, 2) analyze physical symptoms related to ovarian hormones, 3) identify differences between women with PMDD who experienced continued symptom remission and those who experienced symptom recurrence during hormone addback, and 4) determine whether change in hormone levels from baseline to addback is associated with PMDD symptom severity. METHODS: Thirty-four women with PMDD (10 from the original cohort) and 76 healthy participants (15 from the original cohort) completed a daily rating form during three hormone conditions: ovarian suppression induced by the gonadotropin-releasing hormone agonist leuprolide, leuprolide+estradiol addback, and leuprolide+progesterone addback. Affective and somatic symptom scores during the last 8 of 12 weeks of leuprolide alone were compared with scores during the first 4 weeks of estradiol addback and the first 4 weeks of progesterone addback. RESULTS: For affective symptoms (anxiety, sadness, irritability, mood swings), there were significant main effects of diagnosis and diagnosis-by-hormone interactions, reflecting a significant increase in symptom severity scores during estradiol addback and progesterone addback compared with leuprolide treatment alone. Compared to healthy comparison participants, women with PMDD had significantly higher symptom scores during each addback. With regard to physical symptoms, bloating and food cravings showed greater severity in women with PMDD regardless of hormone conditions, whereas breast pain increased in severity during estradiol addback compared with leuprolide alone and progesterone. CONCLUSIONS: The study confirmed that ovarian suppression in women with PMDD eliminated symptom cyclicity, and that symptoms emerged during ovarian steroid addback in women with PMDD but not in healthy comparison women. In PMDD, irritability and mood swings are tied more closely to progesterone than estradiol. Despite the replication of this hormone-related behavioral phenotype in PMDD, the mechanisms underlying the presumed alteration in steroid signaling require further characterization.
引用
- Wei SM, Wakim P, Martinez PE, et al. Differential Effects of Ovarian Steroids in Women With and Without Premenstrual Dysphoric Disorder: A Replication and Extension of Findings. Am J Psychiatry. 2025. PMID: 41030005. doi:10.1176/appi.ajp.20240596
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。